✦ LIBER ✦

A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma

✍ Scribed by Michael H. Veeder; James R. Jett; John Q. Su; James A. Mailliard; John F. Foley; Robert J. Dalton; Paul S. Etzell; Robert F. Marschke Jr.; Carl G. Kardinal; Andrew W. Maksymiuk; Larry P. Ebbert; Henry D. Tazelaar; Geof A. Witrak

Publisher: John Wiley and Sons
Year: 1992
Tongue: English
Weight: 628 KB
Volume: 70
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19921101)70:9<2281::aid-cncr2820700912>3.0.co;2-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase III trial of gemcitabine and carbo

Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma

✍ Sarah Danson; Mark R. Middleton; Kenneth J. O'Byrne; Mark Clemons; Malcolm Ranso 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 325 KB

## Abstract ## BACKGROUND The authors compared gemcitabine and carboplatin (GC) with mitomycin, ifosfamide, and cisplatin (MIC) or mitomycin, vinblastine, and cisplatin (MVP) in patients with advanced nonsmall cell lung carcinoma (NSCLC). The primary objective was survival. Secondary objectives we

Consolidation biochemotherapy for patien

Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin-C) regimen: A phase II study

✍ Diego Tummarello; Francesco Graziano; Pierpaolo Isidori; Antonio Santo; Gianluig 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 632 KB

## BACKGROUND. The authors investigated a consolidation biochemotherapy program with subcutaneous recombinant interleukin-2 (rIL-2) and recombinant interferon-a (rIFNa) biologic response modifiers (BRM) in patients with advanced nonsmall cell lung carcinoma (NSCLC) with responsive or stable diseas

A phase III randomized study of 5-fluoro

A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer

✍ Noe Kyeong Kim; Young Suk Park; Dae Seog Heo; Cheolwon Suh; Si Young Kim; Keun C 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 576 KB

Induction chemotherapy employing dose-in

Induction chemotherapy employing dose-intense cisplatin with mitomycin and vinblastine (MVP400), followed by thoracic surgery or irradiation, for patients with stage III nonsmall cell lung carcinoma

✍ Kenneth K. Ng; Mark G. Kris; Robert J. Ginsberg; Robert T. Heelan; Katherine M. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

## BACKGROUND. Cisplatin-based induction chemotherapy before surgery or irradiation has improved the survival of patients with Stage III nonsmall cell lung carcinoma (NSCLC). Encouraged by earlier results with preoperative MVP (cisplatin [120 mg/m 2 or 25 mg/m 2 /week], vinblastine, and mitomycin)